Robert McRae - Feb 2, 2023 Form 3 Insider Report for PALISADE BIO, INC. (PALI)

Role
Chief Operating Officer
Signature
/s/ Robert McRae
Stock symbol
PALI
Transactions as of
Feb 2, 2023
Transactions value $
$0
Form type
3
Date filed
2/15/2023, 03:40 PM
Next filing
Apr 5, 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding PALI Common Stock 240 Feb 2, 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding PALI Common Stock Purchase Option Feb 2, 2023 Common Stock 1.8K $52.50 Direct F1
holding PALI Series 1 Common Stock Purchase warrant Feb 2, 2023 Common Stock 240 $2.38 Direct F2
holding PALI Series 2 Common Stock Purchase Warrant Feb 2, 2023 Common Stock 240 $2.38 Direct F3
holding PALI Restricted Stock Units Feb 2, 2023 Common Stock 2.62K $0.00 Direct F4, F5, F8
holding PALI Restricted Stock Units Feb 2, 2023 Common Stock 8K $0.00 Direct F5, F6, F8
holding PALI Restricted Performance Stock Units Feb 2, 2023 Common Stock 32.5K $0.00 Direct F5, F7
holding PALI Common Stock Purchase Option Feb 2, 2023 Common Stock 12K $2.40 Direct F5, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents common stock purchase option. The options vest quarterly in twelve (12) equal installments over a three (3) year period.
F2 Represents Series 1 Common Stock Warrants.
F3 Represents Series 2 Common Stock Warrants.
F4 The Restricted Stock Unit vests quarterly on 4/3/23, 7/3/23, 10/3/23, and 1/3/24.
F5 The securities are subject to shareholder approval and: (i) cannot be exercised or converted prior to obtaining shareholder approval, and (ii) the grant can be unwound, and the outstanding securities cancelled, if shareholder approval is not obtained.
F6 Vests quarterly over a three-year period commencing on the grant date.
F7 Vests 50% upon each of the performance milestones being met: (i) the volume weighted average price of the Company's common stock is equal to or greater than $3.20, for a period of twenty (20) consecutive trading days, and (ii) the volume weighted average price of the Company's common stock is equal to or greater than $4.25 for a period of twenty (20) consecutive trading days.
F8 N/A